Conclusions Oral TRT produces significant CV risk .
Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route , as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies
Background Potential cardiovascular ( CV ) risks of testosterone replacement therapy ( TRT ) are currently a topic of intense interest .
However , no studies have addressed CV risk as a function of the route of administration of TRT .
Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men
An important aim in treating male hypogonadism is restoration of physiological concentrations of testosterone and its metabolites . We have assessed hormone levels , pharmacokinetics and clinical response , including safety , of a permeation‐enhanced testosterone transdermal system ( TTD ) in the treatment of hypogonadal men for a 12‐month period
Conclusions Oral TRT produces significant CV risk .
Differences in the degree to which serum DHT is elevated may underlie the varying CV risk by TRT administration route , as elevated serum dihydrotestosterone has been shown to be associated with CV risk in observational studies
Background Potential cardiovascular ( CV ) risks of testosterone replacement therapy ( TRT ) are currently a topic of intense interest .
However , no studies have addressed CV risk as a function of the route of administration of TRT .